Skip to main content
Top

Drugs

Issue 2/2024

Content (11 Articles)

Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges

Camille Allard, Daniela Cota, Carmelo Quarta

Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature

Willemijn A. M. Schonck, Erik S. G. Stroes, G. Kees Hovingh, Laurens F. Reeskamp

Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry

Jonathan Schimmel, Lindsey Claire Epperson, Kim Aldy, Paul Wax, Jeffrey Brent, Jennie Buchanan, Michael Levine, Keith Burkhart

Lumasiran: A Review in Primary Hyperoxaluria Type 1

  • Open Access
  • Adis Drug Evaluation

Connie Kang

Tirzepatide: A Review in Type 2 Diabetes

Nicole L. France, Yahiya Y. Syed

Repotrectinib: First Approval

  • NSCLC
  • AdisInsight Report

Sohita Dhillon

Etrasimod: First Approval

Matt Shirley

Correction to: Nedosiran: First Approval

  • Open Access
  • Correction

Yahiya Y. Syed

Keynote webinar | Spotlight on dry eye disease

  • Live
  • Webinar | 28-05-2026 | 13:00 (CEST)

DED is highly prevalent yet challenging to diagnose and treat. Join leading experts to explore the latest developments and gain practical guidance on effective management in busy clinical settings. Brought to you by Springer Medicine and Eye.

Watch it live: 28 May 2026, 13:00–14:00 (CEST)

Prof. Harminder Dua
Prof. Sajjad Ahmad
Prof. Anat Galor
Join the webinar
Webinar
Image Credits
Conceptual illustration of dry eye disease/© Science Photo Library / Getty Images